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ABSTRACT
Influenza virus can cause life-threatening infections in neonates and young infants. Although vaccination is a major counter-
measure against influenza, current vaccines are not approved for use in infants less than 6 months of age, in part due to the weak
immune response following vaccination. Thus, there is a strong need to develop new vaccines with improved efficacy for this
vulnerable population. To address this issue, we established a neonatal African green monkey (AGM) nonhuman primate model
that could be used to identify effective influenza vaccine approaches for use in young infants. We assessed the ability of flagellin,
a Toll-like receptor 5 (TLR5) agonist, to serve as an effective adjuvant in this at-risk population. Four- to 6-day-old AGMs were
primed and boosted with inactivated PR8 influenza virus (IPR8) adjuvanted with either wild-type flagellin or inactive flagellin
with a mutation at position 229 (m229), the latter of which is incapable of signaling through TLR5. Increased IgG responses were
observed following a boost, as well as at early times after challenge, in infants vaccinated with flagellin-adjuvanted IPR8. Inclu-
sion of flagellin during vaccination also resulted in a significantly increased number of influenza virus-specific T cells following
challenge compared to the number in infants vaccinated with the m229 adjuvant. Finally, following challenge infants vaccinated
with IPR8 plus flagellin exhibited a reduced pathology in the lungs compared to that in infants that received IPR8 plus m229.
This study provides the first evidence of flagellin-mediated enhancement of vaccine responses in nonhuman primate neonates.
IMPORTANCE
Young infants are particularly susceptible to severe disease as a result of influenza virus infection. Compounding this is the lack
of effective vaccines for use in this vulnerable population. Here we describe a vaccine approach that results in improved immune
responses and protection in young infants. Incorporation of flagellin during vaccination resulted in increased antibody and T
cell responses together with reduced disease following virus infection. These results suggest that flagellin may serve as an effec-
tive adjuvant for vaccines targeted to this vulnerable population.
Influenza virus remains one of the leading causes of morbidityand mortality worldwide. Infants less than 6 months of age are
particularly vulnerable to development of severe disease following
infection (1). Diseases associated with influenza virus infection in
children include otitis media, pneumonia, myositis, and croup.
While oseltamivir (Tamiflu), one of the two FDA-approved anti-
influenza drugs, can be used in infants aged 2 weeks and older,
concerns exist due to the potential for adverse effects, drug resis-
tance, and limited effectiveness in young infants (2).
Currently, there are three approved approaches for vaccina-
tion against influenza in the United States: intramuscular (i.m.)
administration of inactivated influenza virus, intramuscular ad-
ministration of recombinant hemagglutinin (HA) proteins, and
intranasal administration of a live attenuated influenza virus
(LAIV). The first is approved for use in individuals aged 6 months
and older, the second for use in individuals aged 18 to 49 years,
and the last for use in healthy individuals aged 2 to 49 years. Thus,
none are approved for use in the vulnerable neonate population.
While the lack of approval for the use of these vaccines in the very
young may reflect some safety concerns, a principal factor is the
poor immune responses elicited in human neonates (3, 4).
Previous studies, while limited, have shown that an initial dose
of the trivalent influenza vaccine (TIV) is not capable of inducing
seroconversion (as defined by a 4-fold increase in antibody titer)
in infants less than 6 months of age, with the exception of one
H3N2 virus strain (A/Mississippi/11/85, for which the conversion
rate was 40% for reasons that are unknown) (3). This low respon-
siveness was not the result of maternal antibody, as all individuals
had prevaccination titers of 1:8. A second dose resulted in sero-
conversion rates of 27 to 32% for H1N1 strains and heterogeneous
responses against H3N2 strains (seroconversion rates, 17 to 93%;
median rate, 32%). Not surprisingly, a correlation between age
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and the rate of conversion was observed, with older infants con-
verting at a higher rate than younger infants (3). In a second study,
in a group of 10- to 22-week old infants, conversion was assessed
following completion of two doses of vaccine, with the conversion
rates being reported to be 42 to 43% for H1N1 strains and 39 to
67% for H3N2 strains (4). For comparison, published studies as-
sessing responses in older children reported that the percentage of
individuals between 11 and 16 years of age with a 4-fold rise in titer
was 90% after a single vaccination (5). Thus, infants respond
poorly to the standard vaccine, even after multiple vaccinations.
The poor responsiveness of this population to vaccination is
not surprising, given the significant body of literature demon-
strating functional defects in the neonatal immune system (6–9).
These defects span the innate and adaptive immune responses.
With regard to the generation of adaptive immunity, dendritic
cells (DCs) from neonates have been reported to produce small
amounts of interleukin-12 (IL-12) and are impaired in their abil-
ity to upregulate costimulatory molecules, e.g., CD80 and CD86,
following exposure to virus-derived signals (e.g., see reference 10).
In addition, lung-resident DCs in neonates have been reported to
have defects in their ability to effectively traffic and activate T cells
following respiratory infection, and this is especially the case for
CD103 DCs, which play a critical role in CD8 T cell priming
(11).
In addition to the impaired function of DCs, T lymphocytes
from neonates exhibit inherent defects in their ability to undergo
activation and differentiation (12–14), including reduced levels of
Lck and ZAP-70 (15), both of which are crucial for the initiation of
signaling, and decreased AP-1-mediated transcription (16). Fur-
ther, T cells in neonates have been reported to be impaired with
regard to migration to the lung following infection (17). The com-
bined deficiencies in DC maturation and T cell responsiveness are
likely major contributors to the impaired T cell responses ob-
served in vivo following infection or vaccination (11, 18–20). In
addition to decreased responsiveness, data suggest a Th2 bias in
the neonate (7). Studies in murine models suggest that this may be
in part due to the IL-4-driven apoptosis of Th1 cells (21) as a result
of the reduced production of IL-12 (22).
Antibody responses are also significantly hampered in neo-
nates (for a review, see reference 6). Important contributors to the
poor antibody response in infants are impaired accessory cells, i.e.,
follicular Th (TFH) cells (23) and follicular DCs (24), as well as
inherent defects in B cell survival and differentiation (25). A po-
tential contributor to diminished survival and differentiation is
the reduced expression of B cell maturation antigen (BCMA) and
BAFF-R on neonate B cells (26). In addition, survival of plasmab-
lasts and differentiation into long-lived antibody-secreting cells in
the neonate are likely hampered by decreased levels of APRIL (27).
Finally, neonates appear to have increases in regulatory B and T
cell populations (28–32).
Recently, it was suggested that select vaccine-adjuvant combi-
nations can allow induction of effective immune responses and
protection in neonates (33). Accumulating data support the idea
that Toll-like receptor (TLR) agonists are effective enhancers of
vaccine-mediated responses (34, 35). Flagellin (flg) is a TLR5 ag-
onist that has proven to be a potent adjuvant for the induction of
antibody responses in a number of experimental animal models
(for reviews, see references 36 and 37). Studies in mice showed
that its inclusion in an inactivated influenza virus vaccine resulted
in enhanced virus-specific antibody and increased protection
(38).
Flagellin promotes adaptive immunity through multiple path-
ways. First, it can directly activate human dendritic cells (39).
Second, flagellin provides a direct stimulatory signal to human T
cells, promoting increases in both proliferation and cytokine pro-
duction (40). In mouse models, it was reported to augment re-
cruitment of T and B cells to secondary lymphoid sites (41). Fi-
nally, a recent study showed that TLR5 is expressed on activated B
cells and plasmablasts and as such can directly promote antibody
responses in mice (42). Thus, the action of flagellin is multifac-
eted, which may contribute to its promising effects in the context
of multiple vaccination approaches.
At present, our understanding of the in vivo adjuvant effects of
flagellin have been derived from studies of adult animals. Here, we
tested the hypothesis that flagellin could serve as an effective ad-
juvant for vaccination of neonates, particularly for vaccination
against influenza. For these studies, we established an infant non-
human primate (NHP) model. This was critical, as the distribu-
tion and/or function of TLR5 in primates can differ from that in
mice (39, 43). For example, flagellin does not directly stimulate
murine T cells (43, 44). An additional critical aspect of this model
is the significantly longer period of infancy in NHPs, which allows
assessment of boosting strategies. Thus, the primate model offers
many advantages for the optimal assessment of the action of
flagellin in neonates.
The results of our studies show that inclusion of flagellin re-
sults in increased influenza virus-specific IgG following both vac-
cination and challenge of neonates. In addition, infants receiving
flagellin-adjuvanted vaccine exhibit increased numbers of influ-
enza virus-specific T cells following virus challenge. These differ-
ences were clinically relevant, as animals vaccinated with inacti-
vated PR8 influenza virus (IPR8) plus flagellin exhibited
decreased lung pathology following virus challenge. These results
support flagellin as a beneficial adjuvant for use in newborns.
MATERIALS AND METHODS
Animals. The African green monkey (AGM) infants (Caribbean-origin
Chlorocebus aethiops sabaeus) used in this study were housed at the Vervet
Research Colony at the Wake Forest School of Medicine. Infants were
removed from their mothers at 1 to 3 days of age and moved to the
nursery. The infants were initially housed in incubators and subsequently
moved to caging when they were capable of thermoregulating. Animal
health was assessed by monitoring body weight, temperature, respiration
rate, heart rate, food intake, and activity throughout the experiment. An-
imals were allowed to acclimate to the nursery for 3 days prior to receiving
the vaccine. All animal protocols were approved by the Institutional An-
imal Care and Use Committee at Wake Forest University School of Med-
icine.
Influenza virus A/PR/8/34 (H1N1). Virus stocks were grown and ti-
ters (50% egg infectious doses [EID50]) were determined in fertilized
chicken eggs essentially as described previously (45). Stocks were diluted
in phosphate-buffered saline (PBS), flash frozen, and stored at 80°C.
Production of flagellin and m229. Flagellin (FliC) from Salmonella
enterica serovar Enteritidis was prepared as previously described (46).
Briefly, Escherichia coli BL21(DE3) containing pet29a::fliC encoding wild-
type flagellin or truncated pet29a::229 encoding only the biologically in-
active hypervariable region of flagellin (inactive flagellin with a mutation
at position 229 [m229]) (47) was grown at 37°C in LB medium containing
kanamycin (25 g/ml) to an optical density (OD) at 595 nm (OD595) of
approximately 0.8. IPTG (isopropyl--D-thiogalactopyranoside) was
then added to a final concentration of 1 mM, and incubation was contin-
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ued for an additional 5 h at 37°C. The cells were chilled on ice and har-
vested by centrifugation at 5,000  g for 15 min. Cell-free lysates were
prepared in 8 M urea, and the proteins were purified on Ni-nitrilotriacetic
acid agarose (Qiagen) according to the manufacturer’s protocol. Endo-
toxin and nucleic acids were removed using an Acrodisc Mustang Q cap-
sule (Pall Corporation). The purified proteins were extensively dialyzed
against PBS, pH 7.2. Protein concentrations were determined using a
bicinchoninic acid protein assay (Pierce).
Vaccination. A/Puerto Rico/8/1934 (H1N1) (PR8), a mouse-adapted
influenza A virus, was inactivated for use in vaccination by treatment with
0.74% formaldehyde overnight at 37°C. Virus was dialyzed against PBS
and tested to ensure the absence of infectivity. At 4 to 6 days of age, infants
were vaccinated with 45 g of IPR8 in combination with 10 g of either flg
or m229 or with PBS as a control by intramuscular injection in the deltoid
muscle (volume, 500 l) (Fig. 1). Animals were boosted 21 days later. Six
infants received IPR8 plus flg (IPR8-flg), five infants received IPR8 plus
m229 (IPR8-m229), and three infants received PBS.
Virus challenge and sampling. On days 23 to 26 following the boost,
the animals were sedated with 2 to 5% inhalant isoflurane. Animals re-
ceived 1  1010 EID50 of strain PR8 divided equally between the intranasal
(i.n.) and intratracheal (i.t.) routes: 0.25 ml i.t. and 0.25 ml i.n. (0.125 ml
per nostril). On each sampling day, the animals were sedated. On days 8
and 14 postinfection, blood was collected by venipuncture and placed in
tubes containing sodium heparin. Plasma was obtained by centrifugation,
and peripheral blood mononuclear cells were subsequently isolated using
the Isolymph reagent. Tracheal washes were performed on sedated ani-
mals on days 2, 5, 8, and 14 postinfection by inserting an endotracheal
tube into the trachea, instilling 1.0 ml sterile PBS, and aspirating back.
Due to the small volume of PBS used in the infants, 0.5 ml of PBS was used
to wash out the endotracheal tube. Samples were centrifuged to remove
cellular material, and bovine serum albumin (BSA) was added to a final
concentration of 0.5%. Bronchoalveolar lavage (BAL) was performed at
necropsy (day 14) using 5 ml of PBS. Samples were centrifuged to remove
cellular material, and BSA was added to a final concentration of 0.5%.
Assessment of lung pathology. The lung was preserved in 10% neu-
tral buffered formalin for at least 24 h, trimmed, embedded in paraffin,
and processed for histology. Sections were cut at 6 m and stained with
hematoxylin and eosin. The slides were examined by light microscopy by
an American College of Veterinary Pathologists board-certified veterinary
pathologist in a blinded fashion and evaluated for the degree of inflam-
mation and injury. Pathology assessment was based on interstitial and
alveolar inflammatory cell infiltration and edema, pneumocyte hyperpla-
sia, and bronchial degeneration and necrosis.
Quantitation of viral load. Viral RNA was extracted from the tracheal
wash using a QIAamp viral RNA minikit (Qiagen). cDNA was synthesized
from mRNA by reverse transcription (RT) using a SuperScript III reverse
transcriptase kit (Invitrogen) and random primers (Invitrogen). For viral
quantification, RNA primer-probe sets specific for H1N1 were used (BEI
Resources). Quantitative RT-PCR (qRT-PCR) was performed using an
Applied Biosystems 7500 real-time PCR system. EID50 were calculated on
the basis of a standard curve generated using a stock of known EID50. The
total EID50 for the sample was calculated on the basis of the amount
present in the sample volume used for the RT-PCR (140 l) and by ad-
justment to the total volume used for the wash.
CRP measurement. The C-reactive protein (CRP) levels in plasma
were assessed at 24 h postvaccination using a C-reactive protein enzyme-
linked immunosorbent assay (ELISA) kit from Alpco Diagnostics per the
manufacturer’s instructions. The absorbance at 450 nm of the plate was
read on a BioTek Elx800 absorbance microplate reader. Amounts were
calculated on the basis of the standard curve generated using the control
provided in the kit.
IL-6 measurement. The amount of IL-6 in plasma at 24 h postvacci-
nation was measured using a human inflammatory cytokine cytometric
bead array (CBA) kit from BD Biosciences per the manufacturer’s proto-
col. Samples were acquired on a BD FACSCalibur system with CellQuest
Pro software (Becton Dickinson). Analysis was performed using FCAP
array software (version 3.0; SoftFlow/BD).
ELISA for detection of influenza virus-specific antibody. Nunc Max-
iSorp ELISA plates were coated with 1 g/well PR8 or 0.2 g/well of
recombinant HA (BEI Resources) in sodium carbonate/bicarbonate coat-
ing buffer (pH 9.5). Plates were blocked with 1 blocking buffer (10
blocking buffer; Sigma) plus 2% goat serum (Lampire Biologicals) and
washed. The wash buffer used throughout the assay was PBS with 0.1%
Tween 20. Plasma or respiratory samples were serially diluted in 1
blocking buffer. Wells without virus served as a negative control. Anti-
body specific for monkey IgG (Fitzgerald), IgM (LifeSpan Bioscience), or
IgA (AbD Serotec) was used to detect bound antibody. IgG and IgM
detection antibodies were directly conjugated to horseradish peroxidase
(HRP). Anti-IgA antibody was biotinylated and was detected with strepta-
vidin-HRP. Plates were developed with 3,3=,5,5=-tetramethylbenzidine
dihydrochloride (Sigma), and the absorbance at 450 nm was read on a
BioTek Elx800 absorbance microplate reader. The absorbance for each
dilution was calculated by subtracting the OD value obtained for the cor-
responding non-virus-coated wells. The threshold titer was defined as the
value that reached 3 times the assay background, i.e., the value for wells
that received only sample diluent.
Neutralization assay. Heat-inactivated (56°C for 1 h) samples were
serially diluted in RPMI 1640 medium supplemented with 2 mM L-glu-
tamine, 1 mM sodium pyruvate, 1 nonessential amino acids (NEAA),
100 U/ml penicillin, 100 g/ml streptomycin, 50 M 2-mercaptoethanol,
and 10% fetal bovine serum (FBS) in a sterile 96-well flat-bottom plate.
Green fluorescent protein (GFP)-tagged PR8 (PR8-GFP; 7.5  106 EID50;
kindly provided by Adolfo Garcia-Sastre [48]) was added to each well, and
the plate was incubated for 2 h at 37°C in 5% CO2 to allow antibody
binding. U937 cells (2  105) were then added to each well, and the plate
was incubated overnight at 37°C. On the next morning, samples were
acquired on a BD FACSCalibur system and analyzed with CellQuest Pro
software (Becton Dickinson) to determine the percentage of U937 cells
that were positive for GFP. Controls for each experiment consisted of
U937 cells alone and U937 cells infected with the PR8 virus-GFP in the
FIG 1 Experimental study design for vaccination and challenge. Neonatal African green monkeys (4 to 6 days old) were vaccinated (day 0 [d0]) and
boosted 21 days later with IPR8 plus either flagellin or the inactive form of flagellin (m229). Control animals received PBS. Blood (B) was drawn on days
1, 10, and 21 after the initial vaccination and days 10 and 21 pb. At 23 to 26 days following the boost, the animals were challenged with live PR8 virus (1010
EID50). On day 14 pc, the animals were necropsied. Tracheal tissue (T) and nasal swab (N) samples were acquired on days 2, 5, 8, and 14 pc, and blood
was acquired on days 8 and 14 pc.
Flagellin Increases Vaccine Responses in Neonates
July 2015 Volume 89 Number 14 jvi.asm.org 7293Journal of Virology
absence of plasma. The maximal percent GFP was calculated for each
experiment, and nonlinear regression (Prism software; GraphPad, La
Jolla, CA) was used to determine the dilution at which 50% of the maxi-
mum amount of PR8-GFP-infected U937 cells was achieved.
Antibody-secreting cell ELISPOT assay. Enzyme-linked immu-
nosorbent spot (ELISPOT) assay plates were coated with 1 g/well of PR8
in PBS and stored overnight at 4°C. Control wells were coated with PBS.
Plates were blocked with RPMI 1640 medium plus 10% FBS and 1%
HEPES for 1 h. Cells were plated and incubated for 6 h at 37°C in 5% CO2.
Plates were washed with PBS plus 0.5% Tween 20. Spots were detected
using anti-IgG-HRP (Fitzgerald) and True Blue substrate (KPL). Spots
were analyzed by use of an ImmunoSpot analyzer (Cellular Technology
Ltd.) and ImmunoSpot (version 3.2) software.
T cell ELISPOT assay. Dendritic cells were generated from bone mar-
row by culture in the presence of granulocyte-macrophage colony-stim-
ulating factor and IL-4 for 6 days. Successful differentiation was assessed
by flow cytometric staining for CD11c. DCs were infected with GFP-PR8
virus (48). Infected or mock-infected DCs were cocultured with autolo-
gous cells for 48 h in ELISPOT assay plates coated with anti-gamma in-
terferon (anti-IFN-	; GZ-4) or anti-IL-4 (IL-4-I) capture antibody
(Mabtech). Following incubation, spots were detected using biotin-con-
jugated anti-IFN-	 (7-B6) or anti-IL-4 (IL-4-II) detection antibody,
streptavidin-HRP-conjugated antibody, and True Blue substrate solu-
tion. Spots were analyzed by use of an ImmunoSpot analyzer (Cellular
Technology Ltd.) and ImmunoSpot (version 3.2) software. For T cell
fractionation experiments, CD8 cells were isolated from total spleno-
cytes using anti-human CD8-phycoerythrin (PE) antibody (clone
2ST8.5H7; Beckman Coulter) and anti-PE microbeads (Miltenyi Biotec).
Statistical analysis. For continuous outcomes, groups were compared
using 2-sample t tests (if the treatment group had two levels) or analysis of
variance (ANOVA) models (if there were three or more levels for the
treatment group), with specific contrasts being defined to compare pairs
of groups when appropriate. If outcome data were not normally distrib-
uted, logarithmic transformations were used prior to the analyses. For
analyses that included repeated measures (i.e., for IgG), a repeated-mea-
sures mixed model was fit, with the primate being considered a random
effect in the model and treatment group and day being considered fixed
effects. The treatment group-by-day interaction was examined first in
these models, and if it was found to be nonsignificant, then that term was
removed. Comparisons between pairs of groups or on particular days
were performed within these mixed models if the overall group or day
effects were found to be significant. Data were analyzed using Prism (ver-
sion 5) software (GraphPad, La Jolla, CA) or SAS (version 9.3) software.
RESULTS
Flagellin promotes a mild inflammatory response in infant
AGMs when added to the inactivated influenza virus vaccine.
The goal of adjuvants is to promote an adaptive immune response
in the absence of deleterious side effects. Innate signals elicited
through engagement of TLR, which was the approach used in our
study, can robustly enhance this process. Infant AGMs were vac-
cinated at 4 to 6 days of age, as outlined in Fig. 1. Infants received
inactivated PR8 in combination with either wild-type flagellin
(IPR8-flg) or inactive flagellin (IPR8-m229). Control animals re-
ceived PBS. To assess safety and immune stimulation as a result of
vaccination in the presence of flagellin, infants were monitored for
changes in temperature, respiration, heart rate, and overall health
every 4 h following receipt of the vaccine. No consistent change in
any of these health indicators was observed (data not shown).
Blood was drawn at 24 h postvaccination to assess C-reactive
protein (CRP) and IL-6 levels as an indicator of systemic flg-me-
diated immune activation/inflammation. We observed a signifi-
cant increase in CRP levels at 24 h postvaccination in animals
receiving the flg-adjuvanted vaccine compared with those in ani-
mals receiving the m229-adjuvanted vaccine (Fig. 2A), with the
overall ANOVA P value for the difference among the three groups
being equal to 0.0021 and with pairwise comparisons of the
groups receiving IPR8-flg and IPR8-m229 with the group receiv-
ing PBS each having P values of less than 0.003. However, while
the CRP level was elevated, this level of CRP is modest and would
not be considered clinically problematic (49). The level of flagel-
lin-induced IL-6 production was heterogeneous among the in-
fants, with three of the six animals exhibiting increases at 24 h
postvaccination (Fig. 2B). Vaccinated infants did not exhibit in-
creases in IL-1, IL-8, IL-10, tumor necrosis factor alpha, or IL-12
levels (data not shown). These findings suggest that these vaccines
are not associated with adverse events in these neonates.
Inclusion of flagellin during influenza vaccination enhances
systemic humoral immune responses in infant AGMs. Produc-
tion of virus-specific antibody was assessed at days 10 and 21 after
the primary vaccination and at the same time points following the
boost. The level of antibody detected at day 1 following primary
vaccination served as a baseline. As shown in Fig. 3A, the presence
of flagellin did not affect the level of virus-specific IgG generated as
a result of primary vaccination (days 10 and 21). However, infants
receiving flagellin-adjuvanted vaccine exhibited significantly in-
creased levels of PR8-specific IgG on day 10 following the boost
compared to infants vaccinated with IPR8-m229. Of note, one
animal that received IPR8-m229 had a markedly heightened re-
sponse compared to that of the other infants (even those that were
vaccinated with the flagellin-adjuvanted vaccine). Outlier analysis
revealed that the response in this animal was significantly different
from that in the remainder of the animals in the group. The reason
for the unusually robust response is not known but may reflect
FIG 2 CRP levels are increased in animals vaccinated with IPR8-flagellin. CRP
(A) and IL-6 (B) levels in the circulation were assessed at 24 h following vac-
cination. The presence of flagellin resulted in significantly increased levels of
CRP in vaccinated infants. IL-6 levels did not differ significantly among the
vaccinated groups. Significance was determined by ANOVA. **, P  0.01.
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genetic factors. The atypical response in this individual is reminis-
cent of the variability in responsiveness that is observed in the
human population, in that sporadic individuals can make an un-
usually robust response (e.g., see references 50 and 51). Inclusion
of the value for this outlier animal in the average revealed the
response in this animal to be significantly different than that of the
remainder of the group. Thus, it was excluded in the remaining
data sets. The repeated-measures-mixed-model fit for these data
showed that there was a significant group-by-day interaction (P 

0.046). Groups were compared at each day to determine where
differences existed. These tests determined that the responses to
IPR8-flg and IPR8-m229 were significantly different by day 10
postboost (pb) (P 
 0.03). Unexpectedly, the level of virus-spe-
cific IgG did not continue to increase through day 21. PBS-in-
jected infants showed no detectable level of circulating PR8-spe-
cific IgG at any time point.
The virus-specific IgM responses in the infants were also as-
sessed. In contrast to what we observed for IgG, while vaccination
induced a modest increase in IgM compared to that in the non-
vaccinated control group, there was no discernible difference be-
tween the two groups of vaccinated animals (Fig. 3B). Thus, the
enhancing effects of flagellin are selective for IgG.
We also assessed the production of IgA following vaccination.
Not surprisingly, given that the vaccine was delivered i.m., virus-
specific IgA levels in plasma were minimal at day 10 pb, the time
point at which maximal virus-specific IgG antibody was detected
(Fig. 3C). Collectively, these data show that the inclusion of flagel-
lin during vaccination significantly enhanced the virus-specific
IgG immune responses in AGM neonates following boost.
An important attribute of protective influenza virus-specific
antibody is the ability to prevent virus infection. To probe the
potential for vaccine-generated antibody to function in this capac-
ity, we assessed the ability of antibody generated as a result of
vaccination to inhibit infection of tissue culture cells by a GFP-
expressing influenza virus (48). Using this approach, we deter-
mined the half-maximal (50%) inhibitory concentration (IC50),
which was defined as the dilution of plasma that inhibited infec-
tivity by 50% compared to the level of infection in the absence of
plasma. This approach was chosen, as it is a direct measure of the
ability of the antibody to prevent infection. This assay was vali-
dated against the standard hemagglutination inhibition (HI) as-
say. Plasma from an independent group of African green monkeys
that were 14 days postinfection with influenza virus was assessed
for the presence of neutralizing antibody using a standard HI assay
or the flow cytometry-based assay. A total of 2.5  105 EID50 was
used for the HI assay and 7.5  106 EID50 was used for the flow
cytometry-based assay. In general, these two assays provided sim-
ilar relative results, although absolute titers were lower in the flow
cytometry-based assay, likely due to the larger amount of virus
used (Fig. 4C).
Surprisingly, at day 10 pb neutralization titers were not signif-
icantly different between animals receiving IPR8-flg and animals
receiving IPR8-m229 (Fig. 4A), even though total influenza virus-
specific IgG levels were higher in IPR8-flg-vaccinated infants. This
suggests that the increase in total influenza virus-specific IgG mea-
sured at day 10 pb was predominantly nonneutralizing antibody.
Interestingly, neutralizing antibody titers remained relatively con-
stant in IPR8-flg-vaccinated animals between days 10 and 21 pb
(Fig. 4A). This contrasts with the findings for IPR8-m229-vacci-
nated animals, where a significant decrease was observed between
days 10 and 21 pb (Fig. 4B). The sustained neutralizing titer in
animals vaccinated in the presence of flagellin is consistent with
the preferential retention of cells producing neutralizing anti-
body. Alternatively, the continued maturation of the response that
includes the preferential generation of cells that produce neutral-
izing antibody could account for this finding.
The presence of flagellin does not promote the generation of
IgG antibody with increased cross-strain recognition. The abil-
ity to induce antibody that is capable of recognizing heterologous
FIG 3 Inclusion of flagellin during vaccination results in an increase in influ-
enza virus-specific antibody selectively following the boost. (A and B) The
levels of PR8-specific IgG (A) and IgM (B) in plasma were measured by ELISA
on days 10 and 21 following prime or boost. (C) The level of PR8-specific IgA
in plasma was measured at day 10 pb. The threshold titer, defined as the
dilution at which the OD450 reached three times the assay background, was
calculated for each animal. Averaged data are shown. The influenza virus-
specific IgG responses at 10 days following the boost observed in infants vac-
cinated with IPR8-flg were significantly increased compared to those observed
in infants vaccinated with IPR8-m229. No differences in IgA or IgM responses
were detected. Significance was determined using a repeated-measures-
mixed-model fit. *, P  0.05.
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strains of influenza virus is a highly desirable attribute of a vaccine.
To determine whether the presence of flagellin impacted this ca-
pacity, we assessed the recognition of A/New Caledonia/20/1999
(H1N1), A/California/07/2009 (H1N1) pdm09, and A/Wiscon-
sin/67/2005 (H3N2). We chose to utilize plasma samples from
infants at day 21 pb, as that amount of time allowed the longest
period for maturation of the antibody response. Overall, there was
limited cross-strain recognition (Fig. 5). While there was modest
recognition of A/New Caledonia/20/1999, when evaluated for dif-
ferential recognition by animals vaccinated in the presence or ab-
sence of flagellin, none was observed. There was no apparent vac-
cine-induced recognition of A/California/07/2009 pdm09 or
A/Wisconsin/67/2005. Together, these data show that the pres-
ence of flagellin does not promote the generation of IgG antibod-
ies capable of cross-strain recognition.
Virus-specific IgG levels are higher after virus challenge in
AGM infants receiving flagellin-adjuvanted vaccine than ani-
mals vaccinated in the presence of m229. The ultimate goal of
vaccination is to establish an immune response that provides en-
hanced protection following pathogen exposure. This is facilitated
by preexisting immunity as well as the capacity to mount a robust
and rapid response to infection. To assess the ability of the vacci-
nated NHP neonates to respond to pathogen challenge, infants
were infected with PR8 virus at 23 to 26 days following the boost.
PR8-specific IgG levels in the circulation and in the respiratory
tract (trachea) were assessed.
Analysis of systemic antibody revealed a highly significant en-
hancement of the recall response in animals immunized with
flagellin-adjuvanted vaccine compared to that in animals receiv-
ing m229 (Fig. 6A). For this comparison, the log2-transformed
plasma IgG levels were compared using a one-way ANOVA, and
the overall test showed a large difference among groups at day 8
(P  0.001). Each of the three pairwise comparisons between the
groups was also statistically significant on the basis of contrasts
performed between groups (P  0.001 for the group receiving PBS
versus the group receiving IPR8-flg, P 
 0.002 for the group re-
ceiving PBS versus the group receiving IPR8-m229, and P 
 0.004
for the group receiving IPR8-m229 versus the group receiving
IPR8-flg). On day 8 postchallenge (pc), PR8-specific IgG plasma
responses in infants vaccinated with IPR8-flg were, on average,
5.6-fold higher than those in infants vaccinated with IPR8-m229.
FIG 4 Inclusion of flagellin during vaccination results in a sustained neutralizing
antibody response at late times postboost. (A) Neutralizing antibody titers in
plasma were determined on days 10 and 21 pb by measuring the inhibition of
infection of U937 cells by a GFP-expressing PR8 virus. The neutralization titer was
defined as the half-maximal (50%) inhibitory concentration (IC50), i.e., the dilu-
tion factor at which 50% infectivity was blocked. (B) The average percent decrease
in the IC50 between day 10 and day 21 for each animal following the boost is
shown. Significance was assessed using Student’s t test. *, P  0.05. (C) Compar-
ison of the neutralizing antibody titers obtained using HI and a flow cytometry-
based assay. Plasma from an independent group of influenza virus-infected Afri-
can green monkeys was tested. PR8-GFP virus was used at 2.5  105 EID50 and
7.5  106 EID50 for the HI and the flow cytometry-based assay, respectively. A
higher level of virus was used for the flow cytometry-based assay to promote in-
fection of the majority of indicator cells. Although absolute titers were lower in the
flow cytometry-based assay, likely due to the larger amount of virus used, the
relative relationships were similar.
FIG 5 Antibody responses generated following vaccination in the presence or
absence of flagellin have similar patterns of cross-reactivity. Plasma obtained
from infants at day 21 pb was assessed by ELISA for the presence of IgG
antibodies capable of recognizing the HA molecule from A/New Caledonia/
20/1999 (H1N1), A/California/07/2009 (H1N1) pdm09, and A/Wisconsin/67/
2005 (H3N2). No significant difference in the capacity to recognize heterolo-
gous strains was detected between animals that were vaccinated in the presence
of flg and animals that were vaccinated in the presence of m229.
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At day 14 pc, plasma antibody levels in infants vaccinated with
IPR8-flg continued to be significantly higher than those in animals
vaccinated with IPR8-m229. The increase in antibody levels fol-
lowing challenge was associated with an increase in antibody-se-
creting cells in the draining tracheobronchial lymph nodes
(TBLNs), although this did not reach statistical significance (Fig.
6B). The presence of neutralizing antibody was also assessed. The
data in Fig. 6C show that IPR8-flg-vaccinated animals exhibited a
significantly higher level of neutralizing antibody following chal-
lenge than their counterparts vaccinated in the presence of m229.
When PR8-specific IgG in the trachea was examined, a correlative
trend toward increased amounts of virus-specific antibody in the
trachea in infants vaccinated in the presence of flg was observed at
day 8 (Fig. 6D).
Vaccination with flagellin promotes robust T cell recall re-
sponses. Influenza virus-specific T cells play a critical role in the
clearance of influenza virus (52). Thus, we assessed the T cell re-
sponse present in vaccinated infants following challenge. IL-4 and
IFN-	 production was assessed by ELISPOT assay, as this ap-
proach provides a highly sensitive readout for antigen-specific
cells. Autologous DCs were generated from bone marrow ob-
tained at necropsy. Differentiated DCs were infected with the
PR8-GFP virus, which allowed assessment to ensure that efficient
infection had occurred. Preliminary studies established that this
approach resulted in the stimulation of both CD4 and CD8 T
cells.
The postchallenge T cell responses in IPR8-flg-vaccinated an-
imals were significantly increased for both IFN-	- and IL-4-pro-
ducing virus-specific cells in the spleen (Fig. 7A). There was also a
trend toward increased influenza virus-specific IFN-	-producing
cells in the lungs in animals vaccinated with IPR8-flg, although
interpretation was complicated by the high variability in IPR8-
m229-vaccinated animals (Fig. 7B). Analysis of samples from a
single late time point is an unavoidable limitation in the assess-
ment of T cell responses in this tissue, as it is performed at nec-
ropsy. Assessment of samples obtained at alternative time points
would be required to know how the early recall responses in the
lungs of IPR8-flg-vaccinated animals versus the lungs of IPR8-
m229-vaccinated animals differ.
We were interested to determine how the production of cyto-
kine was distributed among CD4 and CD8 cells. To address this
question, we developed an isolation approach that did not depend
on CD4 to separate these two populations. This was necessitated
by the understanding that CD4 T cells in AGMs can downregu-
late CD4 and concurrently upregulate CD8 following activation,
resulting in a CD4-low/negative CD8-dim population (53, 54).
CD8 was used to isolated CD8 cells by magnetic separation. In
order to determine how IFN-	 and IL-4 production was distrib-
uted among these populations, we separated splenocytes into
CD8 and CD8 populations. The CD8 population con-
tained CD4 T cells regardless of the activation state. Isolated
populations were stimulated with influenza virus-infected autol-
ogous bone marrow-derived DCs. The data in Fig. 7C are consis-
tent with a flagellin-mediated increase in both CD4 and CD8
cytokine-producing effector cells, although significance was
achieved only for IL-4-producing CD4 cells.
FIG 6 Inclusion of flagellin during vaccination results in an increase in virus-specific total and neutralizing antibody titers following challenge. (A) The influenza
virus-specific IgG antibody titer was measured in plasma at day 8 and day 14 pc. (B) Influenza virus-specific IgG antibody-secreting cells (ASCs) in the draining
TBLNs were quantified at day 14 pc by ELISPOT assay. (C) The neutralizing antibody titer in plasma was measured at days 8 and 14 pc. (D) Analysis of influenza
virus-specific IgG in the trachea at days 2, 5, 8, and 14 postinfection. In panels A, B, and D, significance was determined by a one-way ANOVA. For panel C we
fitted a repeated-measures-mixed-model ANOVA examining the neutralizing titer (log transformed) as the outcome and day, group, and day-by-group effects
in the model. The day-by-group interaction was not significant. *, P  0.05; **, P  0.005; ***, P  0.0005.
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Flagellin-adjuvanted animals show reduced lung pathology
and increased viral clearance after challenge with live PR8 influ-
enza virus. In order to investigate whether inclusion of flagellin
can result in improved protection, we assessed the viral load and
lung pathology in vaccinated and nonvaccinated animals. The vi-
ral load (EID50) was calculated on the basis of a standard curve
generated following RT-PCR with infectious virus (Fig. 8A, right).
Infants vaccinated with IPR8-flg had significantly reduced levels
of virus in the nasal tract at day 2 postinfection compared to in-
fants that received IPR8-m229 (Fig. 8A). Interestingly, at this time
point infants vaccinated with IPR8-m229 appeared to have higher
levels of virus than animals treated with PBS, perhaps suggestive of
an enhancing effect of the vaccine-induced antibodies on infectiv-
ity when adjuvant was not present. While the average level of virus
FIG 7 Infants vaccinated with IPR8-flg have an increased number of influenza virus-specific T cells after challenge. IFN-	- and IL-4-producing influenza
virus-specific T cells in the spleen (A) and lung (B) were measured by ELISPOT assay. The number of both IFN-	- and IL-4-producing cells was significantly
increased in the spleens of infants vaccinated with IPR8-flg compared to the number in the spleens of infants vaccinated with IPR8-m229. (C) Splenic CD8
(CD8 effector) and CD8 (CD4 effector) T cells were isolated from the spleen and stimulated in the presence of autologous DCs exposed to influenza virus.
IL-4- or IFN-	-producing cells were detected by ELISPOT assay. The results for individual animals (individual symbols) and the geometric means (bars) are
shown. Significance was assessed using a Student t test. *, P  0.05.
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was decreased in IPR8-flg-vaccinated infants compared to the
level of virus in animals treated with PBS, this did not reach sta-
tistical significance. We did not observe significant differences in
the average virus burden in the tracheal washes.
Admittedly, this analysis was challenging, as there was substan-
tial variability among the animals. Thus, as another method to
assess the control of virus following challenge, we scored animals
as positive or negative according to whether virus was detected in
the nasal tract and trachea at each time point assessed. This anal-
ysis showed that the proportion of animals that were negative for
FIG 8 The presence of flagellin induces influenza virus-specific immune responses that are capable of increasing virus clearance and decreasing disease. (A) The
virus load in the nasal tract (swabbing) and trachea (wash) was measured following virus challenge of vaccinated animals. At early times following challenge, the
virus titers in the nasal tract of IPR8-flg-vaccinated infants were reduced compared to those in IPR8-m229-vaccinated animals. (B) Percentage of animals in
which virus was undetectable in the nasal tract and trachea at each indicated time following challenge. (C) Representative sections from the lungs of challenged
animals following vaccination with IPR8-flg, IPR8-m229, or PBS are shown. (D) The severity of the lung pathology was determined in a blinded fashion by a
board-certified pathologist. Pathology was assigned as mild, moderate, or marked for each animal. Whereas the majority of animals vaccinated with IPR8-m229
had moderate lung pathology, the majority of animals receiving IPR8-flg exhibited mild disease.
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virus in the nasal tract at day 2 and day 5 was greatly increased for
IPR8-flg-vaccinated infants compared to infants that received
IPR8-m229 (Fig. 8B). Surprisingly, at later times, infants vacci-
nated with IPR8-m229 and, to a lesser extent, infants vaccinated
with IPR8-flg seemed to have a reduced ability to completely clear
virus from the nasal tract compared to nonvaccinated animals.
This was an unexpected finding, given that at early times virus was
undetectable in a large number of the IPR8-flg-vaccinated infants.
Additional studies are necessary to fully define the potential for
upper airway persistence in a small percentage of infants. The
lower respiratory tract (trachea) was also evaluated for the pres-
ence of detectable virus over the course of the infection. Infants
vaccinated with IPR-flg showed improved clearance of virus by
day 8 compared to the clearance observed for infants that received
the m229-adjuvanted vaccine.
In order to address whether the presence of flagellin during
vaccination reduced the severity of virus-mediated disease, lung
pathology was evaluated in a blinded fashion on day 14 postchal-
lenge. A representative section from each group is shown in Fig.
8C. Mild inflammation was characterized by a slight thickening of
the alveolar walls and the minimal presence of intra-alveolar in-
flammatory cells. Moderate inflammation was characterized by
modest thickening of the alveolar walls, perivascular edema, and
regular intra-alveolar cells. Intra-alveolar macrophages were reg-
ularly present. In addition, at a higher magnification, closely
spaced cuboidal epithelial cells, characteristic of type 2 pneumo-
cyte hyperplasia, lining the alveolar walls were occasionally appar-
ent (data not shown). Severe interstitial pneumonia was charac-
terized by diffuse hypercellularity, obscuring the small airways.
Whereas the majority of animals vaccinated with IPR8-m229
had moderate lung pathology, the majority of animals that re-
ceived IPR8-flg exhibited mild disease (Fig. 8D). All nonvacci-
nated infants developed either moderate or marked lung disease.
Taken together, these data suggest that AGM infants vaccinated
with IPR8-flg more effectively clear virus at early time points post-
challenge and display disease scores milder than those for animals
that received IPR8-m229 or PBS.
DISCUSSION
There is a clear need for the development of vaccine approaches
against influenza that are effective in young infants. In addition to
overcoming the immune deficiencies associated with the neonatal
immune system, efforts to achieve this goal are hampered by lim-
itations in appropriate animal models that closely mimic human
infants in immune development as well as in the expression/re-
sponsiveness of molecules that sense the pathogen and immuno-
stimulatory agents. In this study, we have utilized a novel model
for the development of influenza vaccines that can be effective in
neonates. We propose that infant NHPs are a highly advantageous
model as, in contrast to the commonly used mouse model, (i) at
birth the immune system of NHPs more closely mirrors that of
humans (55), (ii) there is a high degree of similarity of NHPs to
humans with regard to the distribution and responsiveness of TLR
receptors (56), and (iii) the NHP lung shares strong similarities
with the human lung in structure and development (57).
In our studies, we found that inclusion of flagellin in an inac-
tivated influenza virus vaccine resulted in superior recall re-
sponses (both antibody and T cell responses) following infection.
We propose that this higher early IgG response has the potential to
limit the spread of influenza and, as a result, reduce the incidence
of disease in the lower respiratory tract. Such a model is supported
by our finding that animals vaccinated in the presence of flagellin
exhibited lower lung pathology.
The ability of flagellin to serve as an effective adjuvant in adults
has been assessed in experimental vaccines against a broad range
of pathogens, including Clostridium, influenza virus, Plasmodium,
Streptococcus, Yersinia, HIV, West Nile virus, Salmonella, Entero-
coccus, Pseudomonas, Campylobacter, Helicobacter, and Burkhold-
eria (for a review, see reference 37). In adult animals, flagellin has
been shown to increase both antibody and T cell responses (for
example, see references 38 and 58 to 62). The promising results in
experimental models (e.g., see reference 61) have led to the eval-
uation of flagellin in phase 1 clinical trials, including as part of an
F1/V fusion protein to protect against plague (http://clinicaltrials
.gov/show/NCT01381744), as a fusion protein with influenza vi-
rus matrix protein 2 (63, 64), or with the influenza virus hemag-
glutinin protein (65, 66). Results from the studies of influenza
virus fusion proteins demonstrate that these vaccines are safe and
immunogenic in healthy adults (63–65) as well as in the elderly
(66). While the efficacy of flagellin has not previously been as-
sessed in neonates, a study with 4- to 6-month-old juvenile mon-
keys found that vaccination with a fusion protein containing
flagellin and the Pseudomonas aeruginosa outer membrane pro-
teins OprI and OprF resulted in a high-affinity IgG antibody that
was capable of providing passive protection against Pseudomonas
aeruginosa infection in a mouse model (62).
The most striking effect of flagellin in our studies with neonates
was in promoting a rapid antibody recall response. This was ap-
parent following boosting as well as challenge. Our initial ratio-
nale for choosing flagellin hinged on its capacity to promote a T
cell response, given the known expression of TLR5 on primate T
cells (67), with the hypothesis that this would support the anti-
body response. Further, there are data supporting the ability of
flagellin to enhance the activation of T cells isolated from infants
(40). Specifically, cord blood-derived CD8 T cells exhibited in-
creased levels of proliferation and IFN-	 production when stim-
ulated in the presence of flagellin (40). While it has not yet been
reported, if flagellin engagement by neonatal CD4 T cells has a
similar effect, which seems likely, given the expression of TLR5 on
CD4 T cells (68), then we would predict that flagellin could
support the generation of a Th response that promotes antibody
production. Our results are consistent with the potential for
flagellin to promote a T cell response, as evidenced by the increase
in influenza virus-specific effector T cells observed following chal-
lenge in animals that were vaccinated in the presence of flagellin.
While naive and memory B cells have been reported to be neg-
ative for TLR5 expression (69, 70), flagellin was recently found to
promote the generation and/or survival of short-lived plasma
cells, and data suggest that TLR5 expression on these cells contrib-
utes to this effect (42). In addition, activated B cells were found to
upregulate the expression of TLR5 (42). These results suggest that
flagellin has the potential to modulate previously activated B cells
as well as short-lived plasma cells. The selective expression of
TLR5 on these two populations would align with the restriction of
flagellin-mediated enhancement of the antibody response to the
boost and challenge phases of our study. The effect at these times
would also be in keeping with the limited time frame of flagellin
persistence following vaccination (J. Bates and S. B. Mizel, unpub-
lished data), as at the time of vaccine administration there would
be TLR5-bearing virus-specific B cells and/or plasma cells that
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could respond to this stimulatory signal. Effects on the short-lived
plasma cells could also account for the unexpected finding that the
flagellin-mediated increase in antibody at day 10 pb did not con-
tinue for a prolonged period, as at day 21 pb antibody levels were
slightly decreased compared to those measured at day 10 pb. If
flagellin is found to have direct effects on short-lived plasma cells,
approaches that would promote the greater survival of these cells
when influenza vaccine is used in combination with flagellin are
avenues for exploration in optimizing the use of flagellin as an
adjuvant for neonates.
The ability of flagellin to modulate immune responses in the
neonate is interesting, given the recent study by Oh et al. reporting
a role for microbiota-dependent TLR5 signaling in promoting
responsiveness to TIV (42). The authors found that signals pro-
vided by gut commensals promoted the humoral response, in-
creasing the quantity of antibody and the frequency of plasma
cells. The flora of humans undergoes significant change through
the first years of life, with adult-like populations being established
at about 3 years of age (for a review, see reference 71). The com-
position of the gut flora has important consequences for vaccina-
tion, as evidenced in a study of human infants receiving an array of
vaccines (72). It is tempting to speculate that the commensals
present in the gut of neonates may provide suboptimal TLR5 sig-
nals, which may be a factor contributing to the poor vaccine re-
sponses in young infants. The presence of flagellin in the vaccine
may compensate for the lack of an endogenous signal, thereby
promoting a more robust antibody response following vaccina-
tion. More studies are needed to determine the extent to which the
gut flora of neonates contributes to vaccine responsiveness and
how adjuvants may overcome any defects associated with the mi-
crobiota of the neonate.
While the effects of flagellin with regard to enhancing recall
responses are promising, the ability to further increase the level of
total and neutralizing antibodies present following a boost is de-
sirable. Recent data suggest that combined signaling through mul-
tiple TLRs may have synergistic effects (73–76). Thus, one ap-
proach to continued improvement of the vaccine strategy for
neonates is the inclusion of additional TLR agonists. In addition to
flagellin, a number of TLR agonists are currently being explored,
and many of these have been clinically evaluated, e.g., poly(I·C) (a
TLR3 ligand), monophosphoryl lipid A (a TLR4 ligand), imi-
quimod (a TLR7 ligand), and CpG (a TLR9 ligand) (77). Whether
the presence of multiple TLR ligands would increase the response
to vaccination in the context of the neonate remains to be tested.
In summary, our study using AGM neonates supports the con-
tinued exploration of flagellin as an effective adjuvant in the con-
text of the neonate. This is especially true with regard to the
induction of responses that can expand rapidly following a sec-
ondary antigen encounter (boost or infection). In our studies, we
found no evidence of adverse effects, suggesting that flagellin is
safe in this population. Future studies evaluating the mechanism
through which flagellin exerts its effects on the recall response will
move us closer to exploiting this adjuvant as a novel vaccine com-
ponent for use in neonates.
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